Both these classes of receptors have demonstrated the capacity to inhibit CD8+ T cell response to tumor, and antibodies that block either of these receptors have been approved by the U.S. Food and Drug Administration for the treatment of patients with cancer. This evidence concerns the gene CD8A and cancer.